Apellis Pharmaceuticals, Inc. — Director's Dealing 2017

Nov 13, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2017-11-13

Reporting Person: Morningside Venture Investments Ltd (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-11-13	Common Stock	C	10778303	—	Acquired	10778303	Direct
2017-11-13	Common Stock	P	575000	$14.00	Acquired	11353303	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-11-13	Series B Preferred Stock	$	C	1054544	Disposed		Common Stock (494394)	Direct
2017-11-13	Series C Preferred Stock	$	C	17200000	Disposed		Common Stock (8063759)	Direct
2017-11-13	Series D Preferred Stock	$	C	4476275	Disposed		Common Stock (2098581)	Direct
2017-11-13	Series E Preferred Stock	$	C	259302	Disposed		Common Stock (121566)	Direct

Footnotes

F1: The Series B, Series C, Series D and Series E Preferred Stock converted into Common Stock on a 2.133-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B, Series C, Series D and Series E Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F2: Louise Mary Garbarino, Jill Marie Franklin, Peter Stuart Allenby Edwards and Raymond Long Sing Tang, the directors of Morningside Venture Investments, Ltd. ("MVIL"), share voting and dispositive control over the shares held by MVIL.